Alerts will be sent to your verified email
Verify Email
KPL
|
Kwality Pharma
|
Venus Remedies
|
Beta Drugs
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
25.27 % | 8.87 % | 22.74 % |
|
5yr average Equity Multiplier
|
1.96 | 1.32 | 1.82 |
|
5yr Average Asset Turnover Ratio
|
1.05 | 0.96 | 1.03 |
|
5yr Avg Net Profit Margin
|
11.66 % | 6.91 % | 12.23 % |
|
Price to Book
|
7.61 | 3.92 | 9.49 |
|
P/E
|
37.44 | 25.31 | 56.03 |
|
5yr Avg Cash Conversion Cycle
|
55.02 Days | 46.96 Days | 7.75 Days |
|
Inventory Days
|
67.04 Days | 75.64 Days | 46.07 Days |
|
Days Receivable
|
132.46 Days | 54.28 Days | 91.57 Days |
|
Days Payable
|
126.93 Days | 58.86 Days | 119.03 Days |
|
5yr Average Interest Coverage Ratio
|
16.13 | 396.11 | 14.42 |
|
5yr Avg ROCE
|
34.73 % | 8.42 % | 27.84 % |
|
5yr Avg Operating Profit Margin
|
23.23 % | 10.14 % | 21.76 % |
|
5 yr average Debt to Equity
|
0.46 | 0.08 | 0.29 |
|
5yr CAGR Net Profit
|
21.34 % | -6.01 % | 29.34 % |
|
5yr Average Return on Assets
|
12.96 % | 6.69 % | 12.69 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
54.87 % | 41.76 % | 64.63 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.13 % | 0.0 | -2.1 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Kwality Pharma
|
Venus Remedies
|
Beta Drugs
|
|
|---|---|---|---|
|
Segment Break-Up
|
Segment Break-Up
|
-
|
-
|
|
Formulations Breakup
|
Formulations Breakup
|
-
|
-
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|